Something Old, Something Blue
A 150-year-old compound, a Nobel Prize origin story, and one of the most interesting mitochondrial tools I’ve come across. I’ve been taking it for two years.
This is a bit of a continuation from last week's Mitochondrial Triad post...a spotlight on the elusive fourth pillar of mitochondrial optimization. A sort of efficient cousin who shows up to the family reunion, skips the small talk, and just starts fixing things nobody else knew were broken.
I’ve been taking methylene blue for about two years now, and it’s one of those compounds that surprised me by having an immediate and positive effect. But the most interesting thing about this compound is its story. This compound has been used in medicine since 1891. It was the first fully synthetic drug ever administered to a human being, and it’s on the WHO’s List of Essential Medicines.
I’ll walk you through the history (which is genuinely fascinating), the mechanism (which is unlike anything else I take), the brain research (which is early but compelling), and the safety considerations (which are serious and worth reading closely). And I’ll tell you what I personally notice after two years of daily use.
Let’s get into it.
A Brief History of Methylene Blue
This might be my favorite origin story in longevity science, because methylene blue didn’t come from a lab trying to solve aging. It came from a lab trying to dye cotton.
In 1876, a German chemist named Heinrich Caro at BASF was experimenting with coal tar derivatives when he produced a vibrant blue dye. BASF patented it the following year; Germany’s first patent for a synthetic dye. It was meant for textiles. That’s it. Blue fabric.
Then a young physician named Paul Ehrlich got his hands on it and changed everything.
Ehrlich noticed that methylene blue could selectively stain certain cells while leaving others untouched. By 1881, he was using it to visualize bacteria under a microscope. By 1885, he’d figured out it could make individual neurons visible. And by 1891, Ehrlich and his colleague Paul Guttmann used methylene blue to treat two malaria patients in a Berlin hospital; the first time a fully synthetic compound was ever used as a drug in human medicine. Before aspirin. Before antibiotics. Before any of it.
That selective staining property led Ehrlich to develop what he called the “magic bullet” concept; the idea that a chemical could be designed to target specific biological structures. That concept became the foundation of modern chemotherapy, antihistamines, and entire classes of psychiatric medication. Ehrlich won the Nobel Prize in 1908. All of it traces back to a blue dye on a cotton bolt.
After that, methylene blue carved out a long career in medicine. It was used as a malaria treatment through two World Wars. In 1933, Matilda Brooks discovered it could reverse cyanide and carbon monoxide poisoning. It became the standard treatment for methemoglobinemia (a blood disorder where hemoglobin can’t carry oxygen properly), which is still its only FDA-approved use today. Surgeons still use it to map lymph nodes and identify tissue structures. It’s on the WHO’s List of Essential Medicines.
And now, 150 years after it was invented to dye fabric, researchers are studying it for something else entirely: keeping aging mitochondria running.
How Methylene Blue Works (The Mitochondrial Story)
This is the part of the story I find most fascinating, and it’s the reason I started taking it.
Your mitochondria; the power plants inside every cell; produce energy (ATP) through a process called the electron transport chain. Think of it as a bucket brigade with five stations (Complexes I through V). Electrons get passed from one station to the next, and at each handoff, a little bit of energy is captured and stored as ATP. When all five stations are working well, the brigade moves smoothly.
As we age, two of those stations start to falter: Complex I and Complex III. They slow down, drop electrons, and generate more oxidative stress (free radicals) as a byproduct. Less energy gets produced, more cellular damage accumulates. This is not a minor footnote…mitochondrial dysfunction is considered one of the central hallmarks of aging.
Methylene blue does something unusual. Because of its chemical structure, it can accept and donate electrons on its own. It cycles between two forms; an oxidized form (blue) and a reduced form called leucomethylene blue (colorless). Inside your mitochondria, it can step into the bucket brigade and pass electrons directly to Complex IV (cytochrome c oxidase), bypassing the sluggish stations entirely.
In plain English: when your normal energy production line slows down with age, methylene blue acts like a shortcut that keeps the power flowing.
The numbers from cell and animal studies are striking. A single low dose increased cytochrome c oxidase activity (the enzyme at Complex IV) by 30%, boosted cellular oxygen consumption by up to 70%, and increased ATP production by approximately 30%. And because it bypasses the stations that leak the most free radicals, it actually reduces oxidative stress while increasing energy output.
That’s not how most antioxidants work. Most antioxidants neutralize free radicals after they’ve already been created; cleaning up the exhaust. Methylene blue reduces the exhaust being produced in the first place, while simultaneously making the engine more efficient.
In plain English: methylene blue doesn’t just mop up cellular damage. It makes the system that creates the damage work better, so there’s less mess to begin with.
The Hormetic Curve: Why More Is Not Better
This is the section I think everyone considering methylene blue needs to understand, because the dose-response is not intuitive.
Methylene blue follows a classic inverted U-shaped dose response. At low concentrations, it’s an antioxidant and mitochondrial supporter. At high concentrations, it flips and becomes pro-oxidant; generating the very damage it’s supposed to prevent.
The research is specific. In cell studies, concentrations of 0.5 to 5 micromolar enhance Complex IV activity. Above 10 micromolar, that same activity gets suppressed. In animals, 0.5 to 4 mg/kg improves memory and mitochondrial function. Above 10 mg/kg, it impairs them. Clinically, the threshold for toxicity sits around 7 mg/kg cumulative. That’s well above longevity doses, but the principle is critical.
In plain English: with methylene blue, there is a very real sweet spot. Hit it, and your mitochondria run better. Overshoot it, and you’re doing the opposite of what you intended.
At the molecular level, this makes sense. At low doses, methylene blue forms molecular pairs (dimers) that interact constructively with the electron transport chain. At high doses, those pairs break apart into individual molecules (monomers) that disrupt electron flow and increase free radicals. The molecule literally changes behavior depending on concentration.
I take a low dose. I’ve stayed low for two years. This is one of those situations where restraint is the whole strategy.
What the Brain Research Says
The brain uses roughly 20% of your body’s total energy while representing about 2% of body mass. Neurons are enormously energy-dependent, which makes them especially vulnerable to mitochondrial decline. When brain mitochondria lose efficiency, you don’t just lose energy; you lose memory consolidation, attention, processing speed, and over decades, the ability to clear the protein aggregates associated with neurodegeneration.
Methylene blue crosses the blood-brain barrier easily and concentrates in brain tissue at about 10 times serum levels within an hour. It preferentially accumulates in hippocampal neurons; the exact cells responsible for memory formation.
Dr. Francisco Gonzalez-Lima and his team at the University of Texas have done some of the most careful human work on this compound. In a 2016 fMRI study published in Radiology, 26 healthy volunteers received a single dose of methylene blue and then performed memory tasks inside a brain scanner. The MB group showed a 7% improvement in memory retrieval accuracy and significantly increased activation in the prefrontal cortex, parietal cortex, and occipital regions.
A second fMRI study from the same lab found that methylene blue enhanced resting-state functional connectivity in brain networks responsible for attention and working memory.
And a randomized controlled trial published in the American Journal of Psychiatry found that a single dose of methylene blue doubled the rate of contextual memory retention one month later in a fear extinction protocol.
In plain English: in healthy humans, methylene blue appears to improve how the brain forms and retrieves memories, and the effect shows up on brain imaging.
These are small studies with single doses. We don’t have long-term data on daily use in healthy people. The work is promising and well-designed, but it’s early.
The Alzheimer’s Connection
There’s a parallel story here that’s been unfolding for decades, and it’s worth understanding because it comes up a lot.
In 1988, a researcher named Claude Wischik at Cambridge discovered the structure of tau protein tangles; one of the hallmarks of Alzheimer’s disease. By the mid-1990s, he found that the methylthioninium class of compounds (which includes methylene blue) could dissolve those tangles in the lab.
This led to TauRx Therapeutics, which developed a modified form of methylene blue called LMTM (hydromethylthionine mesylate) specifically for Alzheimer’s. There have now been multiple phase 3 clinical trials. The most recent, the LUCIDITY trial published in January 2026 in the Journal of Prevention of Alzheimer’s Disease, showed that patients with mild cognitive impairment experienced an 82% reduction in cognitive decline and a 35% reduction in brain atrophy over 78 weeks when taking the drug as a standalone treatment.
Those are compelling numbers. But the compound used in these trials is not the same thing as the methylene blue you’d buy in drops or capsules. LMTM is a chemically distinct derivative, engineered for better absorption and brain penetration. Saying “methylene blue fights Alzheimer’s” based on this research is like saying grapes cure heart disease because resveratrol showed promise in a lab. The relationship is real, but the distance between them is significant.
In plain English: the Alzheimer’s research is exciting, but it’s based on a pharmaceutical cousin of methylene blue, not the compound itself. They share a family tree, not a resume.
The Safety Section (Try Not to Skim this Part)
I spend time on safety in these posts because I think it’s the part that actually matters for decision-making. Methylene blue has a few things you need to know about before you consider it.
Grade Matters. A Lot.
Methylene blue is sold in three grades, and only one is safe for humans.
Pharmaceutical / USP grade: The only grade that meets USP Monograph #2351 standards for purity (at least 98%), heavy metal limits (20 ppm or less), and contamination testing. This is what you want.
Lab / reagent grade: Made for research. Not tested or intended for human consumption.
Industrial / aquarium grade: Made for dyeing textiles and treating fish parasites. Can contain heavy metals, solvents, and toxic byproducts. Costs $5 to $15 online. Do not take this.
If the product you’re looking at doesn’t come with a lot-specific Certificate of Analysis from an accredited lab...walk away. The safest route is through a compounding pharmacy with a prescription, which is how I access mine.
Serotonin Syndrome: The Interaction That Can Kill You
This is the safety issue I think deserves the most attention. Methylene blue is a potent inhibitor of monoamine oxidase A (MAO-A); the enzyme that breaks down serotonin in your brain. On its own, at low doses, that’s part of why some people report mood benefits.
But if you combine methylene blue with any drug that also raises serotonin; SSRIs (like Zoloft, Lexapro, Prozac), SNRIs (like Effexor, Cymbalta), MAOIs, certain opioids, tramadol, even St. John’s Wort; you risk serotonin syndrome. The FDA has issued a black-box warning about this. At least one death has been documented.
Serotonin syndrome symptoms include agitation, confusion, rapid heart rate, high blood pressure, muscle rigidity, tremor, and in severe cases, seizures and coma.
If you are on any serotonergic medication, methylene blue is off the table unless you’ve worked out a supervised washout plan with your prescriber. Fluoxetine (Prozac) requires a five-week washout; most other SSRIs require at least two weeks.
In plain English: methylene blue and antidepressants do not mix. This is not a “proceed with caution” situation. It’s a hard no unless your doctor is specifically managing the transition.
G6PD Deficiency
G6PD deficiency is a genetic condition that affects over 400 million people worldwide, particularly those of African, Mediterranean, Middle Eastern, and Southeast Asian descent. Many people don’t know they have it. In G6PD-deficient individuals, methylene blue can cause hemolytic anemia; the destruction of red blood cells; which can show up 24 to 72 hours after taking it. If you’re considering methylene blue, getting tested for G6PD deficiency is a reasonable first step. It’s a simple blood test that rules out a serious risk.
Because it Bears Repeating: Who Should Think Twice
Anyone on SSRIs, SNRIs, MAOIs, or other serotonergic medications. The interaction risk is real and documented. This is the most important contraindication.
Anyone with G6PD deficiency (or who hasn’t been tested and is from a high-prevalence population).
Pregnant or nursing women. Methylene blue has been associated with fetal harm, and the ProvayBlue prescribing information recommends an 8-day breastfeeding moratorium after exposure.
Anyone with significant kidney impairment. MB is renally excreted, and impaired clearance increases the risk of accumulation.
If none of those apply and you’re curious, this is a conversation to have with a physician who understands longevity medicine; not a decision to make based on someone else’s experience alone.
My Experience
I started taking methylene blue about two years ago after spending a lot of time with the mitochondrial research. I was already deep in the peptide world (BPC-157, epitalon, GHK-Cu...you know the list by now) and methylene blue kept showing up in the longevity literature as a different kind of tool; not a peptide, not a supplement in the traditional sense, but a compound with a real pharmacological mechanism that I found genuinely interesting.
What I notice: I feel sharper. My energy is more consistent throughout the day. My focus is better, and I don’t hit the afternoon wall the way I used to. These are subjective observations; I’m not pretending they constitute clinical evidence. But two years of consistent use is a meaningful personal dataset, and I notice a difference. The most impact is on days when the previous night’s sleep wasn’t amazing…when brain fog is most certainly creeping in early.
I source mine through a compounding pharmacy, pharmaceutical grade, in capsule form. Low dose. I’ve never gone high, and I don’t plan to, because the hormetic curve tells me exactly what would happen if I did...and I’d rather stay in the sweet spot.
If you don’t have access to a compounding pharmacy and the prescription it requires, a brand I trust (and am actually currently using to try out their multi-supportive formulation) is MitoBlue from LVLUP. So far, so great!
And yes, if you take the liquid drops, your tongue turns blue. It’s temporary. Also, your urine can turn blue-green, which is completely harmless; it just means the compound is being excreted...surprise!
In Case You Skimmed
Methylene blue was synthesized in 1876 as a cotton dye and became the first fully synthetic drug used in medicine when Paul Ehrlich used it to treat malaria in 1891. Ehrlich went on to win the Nobel Prize, and his “magic bullet” concept became the foundation of targeted drug therapy.
Its primary mechanism of interest for longevity is mitochondrial support: it acts as an alternative electron carrier in the electron transport chain, bypassing age-related dysfunction at Complex I and Complex III and delivering electrons directly to Complex IV.
The dose-response is hormetic (inverted U-shape): low doses enhance mitochondrial function and act as antioxidants; high doses flip to pro-oxidant and cause harm. More is not better.
Small human studies show improved memory retrieval, enhanced brain connectivity, and doubled contextual memory retention; but these are single-dose studies and long-term data in healthy people doesn’t exist yet.
The Alzheimer’s trials (TauRx / LUCIDITY) use a pharmaceutical derivative of methylene blue (LMTM), not the compound itself. Promising results, but it’s not the same thing.
Only pharmaceutical / USP grade is safe for human use. Industrial and aquarium-grade methylene blue contains heavy metals and contaminants.
Methylene blue is a potent MAO-A inhibitor. Combining it with SSRIs, SNRIs, or other serotonergic drugs risks serotonin syndrome, which carries an FDA black-box warning and has been fatal.
G6PD deficiency is a hard contraindication; get tested before starting.
I’ve been taking it for two years, low dose, pharmaceutical grade. I notice better focus, more consistent energy, and less afternoon cognitive fade. I’m staying on it.
I think methylene blue is one of the more interesting compounds in the longevity space right now; it’s a compound that demands respect, the safety profile is excellent at low doses, but the drug interactions and sourcing risks are not trivial.
If you’re curious, start with a conversation with your longevity doctor, make sure you’re not on anything that interacts, confirm your G6PD status, and source it properly. And if you end up trying it, don’t panic when you pee blue/green…and also don’t panic if you don’t. If you start it on a Monday, see how you feel that same Monday and the following Mondays.
See you then,
Susan
Longevity in the Wild
At least once a day, a friend or family member sends me an Instagram post or screenshot with the same question: What do you think about this?
Usually, I can bat it back quickly…a thumbs up or down with a one-line explanation. But the other day, I got one that actually stopped me. A molecule inhibitor I had never heard of, tied to a question that immediately pulled me in: Ever hear of this for knee cartilage regrowth? The image: screenshot about 15-PGDH with the caption: “Scientists just regrew knee cartilage in one shot.”
…okay, now you have my attention. Down the rabbit hole I went.
15-PGDH is actually pretty interesting. It’s an enzyme we have naturally that breaks down prostaglandins, the signaling molecules involved in inflammation, pain, blood flow, and tissue repair. Stay with me, because this is where it gets counterintuitive: once those signals have done their job, 15-PGDH swoops in and turns them off.
What’s being explored in longevity circles is the opposite approach: inhibiting 15-PGDH. In other words, easing off the “off switch” so those repair signals stick around longer, potentially allowing the body to send more help to damaged tissue. It’s essentially approaching healing from the other direction. Conceptually, this reminds me of 5-amino 1MQ…working by removing a constraint rather than adding something new. It’s a compelling idea, especially when you think about older injuries the body has stopped prioritizing. That said, this is still very early. The mechanism makes sense on paper, but human data isn’t there, and these same pathways are tightly tied to inflammation, so more isn’t automatically better. For now, I’m intrigued enough to keep watching…just not jumping in. Stay tuned.